H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Exelixis (EXEL) to $46 from $53 and keeps a Buy rating on the shares. The firm cites the company’s decision not to proceed to the Phase 3 portion of the STELLAR-305 trial for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: